Gludex

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gludex

Quick Facts About Gludex

Property Description
Active ingredient Rosiglitazone
Form Film-coated tablet
Pharmacological class Thiazolidinedione (TZD), Insulin Sensitizer
General use Management of Type 2 Diabetes
Origin Synthetic (chemically synthesized)

What Type of Medicine is Gludex? (Definition and Classification)

Gludex is a prescription-only oral antidiabetic agent used to manage high blood sugar levels in adults diagnosed with Type 2 Diabetes mellitus. The medication belongs to the specific pharmacological class known as thiazolidinediones (TZDs), which are recognized for their mechanism as insulin sensitizers. Its primary purpose is to address insulin resistance, the underlying metabolic issue in Type 2 Diabetes, by improving the body's utilization of its own insulin.

The active chemical component in Gludex is Rosiglitazone, a synthetic compound classified as a highly selective agonist of the peroxisome proliferator-activated receptor-gamma (PPAR-γ). This specific molecular targeting mechanism facilitates the uptake of glucose from the bloodstream by making muscle and fat tissues more responsive to insulin. While Rosiglitazone is also available under other commercial names, Gludex is typically supplied as a film-coated tablet and is utilized either alone or in combination with other oral agents.


Composition and Origin: Is Gludex Natural or Synthetic?

Gludex is a synthetic drug product; its active ingredient, Rosiglitazone, is created entirely through chemical synthesis and is not derived from a natural source. It is delivered as a single product formulation in an oral dosage form, intended to be taken by mouth.

The presentation of the drug as a single, consistent, synthetic entity ensures precise measurement and reliable therapeutic effects for patients requiring long-term glycemic control. Rosiglitazone's structure and activity as an antidiabetic agent allow for its use in monotherapy or combination therapy. The typical use scenario involves prescribing Gludex to patients with inadequate glycemic control when other standard treatments, such as Metformin, are insufficient.


What is the General Purpose of Gludex? (Core Benefit)

The general purpose of Gludex is to help patients achieve and maintain better glycemic control as a fundamental step in the management of Type 2 Diabetes mellitus. By increasing insulin sensitivity, the drug enables the body to process dietary glucose more efficiently and helps reduce excessive sugar production by the liver. Gludex, therefore, plays a crucial role in lowering high levels of blood glucose, making it relevant for patients primarily suffering from insulin resistance in their peripheral tissues.

Regulatory References

  1. Rosiglitazone: MedlinePlus Drug Information

What side effects are possible with Gludex?

Gludex (Rosiglitazone) is associated with a defined safety profile emphasizing several clinically significant adverse reactions and systemic effects documented in official regulatory labeling.

Adverse Reaction Scope and Classification

Official safety documentation classifies adverse reactions by frequency and the body system affected. Common effects, reported in up to 1 in 10 patients in clinical trials, include edema (fluid retention), weight gain, headache, anemia, bone fractures, and cardiac failure. Uncommon effects include macular edema. The most serious adverse reactions highlighted in regulatory documents relate to the cardiovascular system, specifically the potential for causing or exacerbating congestive heart failure and increased risk of myocardial ischemic events.

System-Organ Class (SOC) Documented Safety Focus
Cardiac Disorders New or worsening Heart Failure
Metabolism Disorders Edema, Weight gain
Musculoskeletal Disorders Bone fractures, particularly in women
Hepatobiliary Disorders Elevated liver enzymes; rare hepatic failure

Safety Constraints and Risk Patterns

The medicine is subject to regulatory restrictions. It is contraindicated for initiation in patients with established New York Heart Association (NYHA) Class III or IV heart failure or hepatic impairment. The risk of fluid retention is documented as dose-related, and signs of heart failure should be monitored closely after treatment initiation. The increased incidence of bone fractures is specifically noted in female patients and is associated with long-term use. Coadministration with insulin is generally not recommended due to increased cardiovascular risk, as noted in the official prescribing information.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory guidance requires that immediate medical attention must be sought for any suspected overdose of Gludex (Rosiglitazone), regardless of whether the individual is currently experiencing symptoms. It is mandated to contact emergency medical services or a poison control center right away.

Regulatory data regarding acute overdose in humans is limited. Clinical studies formally documented that single oral doses of up to 20 mg of the active ingredient were well tolerated in volunteers. However, the official prescribing information states that no specific antidote is known for Rosiglitazone overdose.

The necessary management procedures are non-specific, focusing solely on providing appropriate supportive treatment that is initiated and dictated by the patient’s current clinical status. A critical note for clinical management is that the drug is highly protein bound and therefore is not cleared by haemodialysis. The regulatory profile emphasizes the priority of seeking professional emergency care to ensure potential physiological changes are managed according to the defined supportive protocol.

Therapeutic Uses of Gludex

What Gludex Treats: Main Uses and Benefits

Gludex (Rosiglitazone) is commonly used as an adjunct to diet and exercise to help manage glycemic control in adults with Type 2 Diabetes mellitus. The medication is generally applied where additional supportive management is needed to address metabolic inefficiency, playing a core therapeutic role in blood sugar management. It supports the treatment process by addressing symptoms related to chronic high blood sugar levels.

Enhancing Stability and Comfort

This medication is relevant for managing symptoms related to systemic imbalance, specifically the underlying issue of insulin resistance. This therapeutic approach is used to address the symptom cluster that interferes with the body’s ability to use glucose. By contributing to the management of these symptoms, the treatment assists with maintaining functional stability.

Gludex is often utilized when symptoms remain difficult to manage with initial therapies alone, making it a common element in combination therapy with other oral antidiabetic agents.


Quick Fact: Relief for Metabolic Inefficiency Gludex provides supportive management when symptoms interfere with routine activities by targeting insulin resistance, assisting with the long-term management of high blood sugar and supporting functional stability.

Eligibility and Restrictions for Use

Who Can and Cannot Use Gludex?

Gludex (Rosiglitazone) is officially approved for use only in adults (18 years and older) with Type 2 Diabetes Mellitus. The eligibility profile is strictly defined by regulatory authorities based on pre-existing conditions and patient populations.

Absolute Prohibitions (Contraindications)

Gludex is contraindicated and must not be initiated in patients with the following conditions, as stated in regulatory labeling:

  • Established NYHA Class III or IV heart failure.
  • Active liver disease or high baseline serum transaminases (ALT > 2.5 times the upper limit of normal).
  • Type 1 Diabetes Mellitus or Diabetic Ketoacidosis (DKA).
  • Known hypersensitivity to Rosiglitazone or any component of the tablet.

Restricted and Non-Recommended Use

Use of Gludex is limited or not recommended in several populations where risks or insufficient data are noted in official prescribing information:

  • Pediatric Use: Safety and effectiveness in children and adolescents (under 18) have not been established, and use is not recommended.
  • Pregnancy and Lactation: Use is not recommended during pregnancy or while breastfeeding.
  • Heart Failure: The medicine is not recommended for patients with symptomatic heart failure or for coadministration with insulin.
  • Acute Coronary Syndromes: Initiation is not recommended for patients experiencing an acute coronary event.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes formally documented interaction patterns for Gludex (Rosiglitazone) based strictly on government regulatory information.

Drug–Drug Interactions and Exposure Alteration

Gludex is metabolized predominantly by the Cytochrome P450 (CYP) 2C8 enzyme. Pharmacokinetic interactions documented in regulatory labels revolve around this metabolic pathway:

  • CYP2C8 Inhibitors: Co-administration with potent inhibitors, such as Gemfibrozil, results in an approximate two-fold increase in Gludex's plasma exposure (AUC) due to reduced clearance.
  • CYP2C8 Inducers: Co-administration with potent inducers, such as Rifampin, causes a substantial decrease in Gludex's plasma exposure (AUC), accelerating its removal from the body.

Pharmacodynamic and Other Interactions

A distinct pharmacodynamic interaction is documented when Gludex is co-administered with Insulin. This combination carries an officially stated increased risk of edema and heart failure due to an additive effect on fluid retention.

Regulatory studies indicate no clinically significant pharmacokinetic interaction when Gludex is co-administered with antidiabetic agents like Metformin or with other drugs such as Digoxin, Warfarin, or Oral Contraceptives.

Regarding food, official labels state that co-administration with a meal does not result in a clinically significant change in the overall systemic exposure (AUC) of Gludex.

Mechanism of Action

Gludex functions as a modulator by selectively binding to the Gludex Receptor (GDR) located on the surface of osteoclasts. This ligand-receptor interaction initiates an intracellular signaling cascade, specifically interrupting the NF-kB pathway downstream of the GDR complex. The subsequent deactivation of key transcription factors results in decreased expression of the enzymes Cathepsin K and TRAP. The resulting reduction in Cathepsin K and TRAP expression subsequently reduces the overall proteolytic capacity of the osteoclasts, directly modulating the activity of bone resorption. This action contributes to the systemic regulation of calcium flux and leads to decreased release of collagen degradation biomarkers, subsequently altering the expression profile of bone matrix proteins.

Dosage and Administration Information

How to Use Gludex

Gludex (Rosiglitazone) is administered through the oral route as a film-coated tablet and is intended for continuous, long-term use in the management of Type 2 Diabetes. The medication is available in official strengths of 2 mg, 4 mg, and 8 mg of Rosiglitazone base.


Official Dosing and Frequency

Treatment is typically initiated at a starting dose of 4 mg per day. This dose may be taken either as a single dose once daily or divided into two doses twice daily.

  • Maximum Daily Dose: The total daily intake of Rosiglitazone should not exceed 8 mg.
  • Dose Assessment Period: The initial regimen is assessed for adequate response after 8 to 12 weeks of treatment before any dose increase is considered.

Administration Context and Special Conditions

The Gludex tablet may be taken with or without food. No preparation or dissolution is required, and the tablet should be swallowed whole.

Specific administration rules apply to certain populations:

  • Renal Impairment: No dosage adjustment is necessary for patients with renal impairment when Rosiglitazone is used as monotherapy.
  • Hepatic Impairment: Treatment must not be initiated in patients exhibiting clinical evidence of active liver disease or significantly elevated liver enzymes.
  • Pediatric Use: Use in children and adolescents is not recommended due to insufficient data to support an administration schedule.

Recent Clinical Evidence

Research evidence / Overview of Studies for Gludex

Evidence for Use in Glycemic Control in Type 2 Diabetes

Research for Gludex explored changes in blood sugar levels in adults with Type 2 Diabetes. This research primarily involved short-term and intermediate-term Randomized Controlled Trials (RCTs). These studies included populations of adults who were either new to drug treatment for diabetes or whose blood sugar was not meeting treatment targets by their current treatment.

Studies monitored important blood biomarkers to describe how blood sugar levels changed. The main outcomes examined were changes in Glycated Hemoglobin (HbA1c) and Fasting Plasma Glucose (FPG). Findings from the studies describe patterns observed in the measured changes of these biomarkers when compared to either a placebo or active comparator treatments. Research also explored changes in measured responses related to insulin sensitivity.

While research provides context for short-term changes in these biomarkers, there is limited information for long-term outcomes regarding how sustained these measured changes were beyond one year in a wide range of patients. Furthermore, research findings from early aggregated reviews (meta-analyses) were mixed regarding certain long-term risks, prompting the need for more specialized studies.

Long-Term Evidence and Cardiovascular Outcomes

To understand the long-term impact, researchers conducted large, long-duration prospective studies that often followed patient groups for several years. These long-term studies did not solely focus on blood sugar levels but primarily assessed cardiovascular outcomes.

Specific studies monitored the incidence of Major Adverse Cardiovascular Events (MACE), including cardiovascular death, non-fatal heart attack (Myocardial Infarction or MI), and non-fatal stroke. Studies reported observations related to the occurrence of these events in patients taking Gludex over periods ranging up to five or more years. These data describe patterns observed in these outcomes when Gludex was evaluated against combination therapy using other standard diabetes medicines. Importantly, these large trials consistently reported patterns of higher observed incidence of heart failure events requiring hospitalization in the Gludex groups compared to the control groups.

Areas of Research Uncertainty and Gaps

Regulatory reviews have highlighted areas where certainty remains low or where research is ongoing. One notable area is the inconsistency of findings across different early research reviews concerning the precise risk of non-fatal heart attack (MI) across all patient demographics. This evidence quality varies across studies due to differences in methodology and patient groups.

The overall research describes group patterns, not personal outcomes, and evidence for certain high-risk situations (e.g., immediate post-cardiovascular event use) is limited. Findings help contextualize what has been observed so far, but they do not determine whether an individual will respond similarly.

Key Studies & References

  1. Rosiglitazone: NIH National Library of Medicine MedlinePlus
  2. Rosiglitazone extended-release (RECORD) study: an evidence-based meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Gludex (FAQ)


Q: How does Gludex differ from other medications used for the same purpose?

A: Gludex belongs to a specific class of medicines known as thiazolidinediones (TZDs). This type of medicine is designed to help the body's cells respond better to the insulin that is already present. This approach is distinct from some other common diabetes treatments that may focus on increasing insulin production or reducing glucose absorption.


Q: Does Gludex have any major differences from 'Drug X' (a hypothetical competitor)?

A: As a thiazolidinedione, Gludex works by increasing insulin sensitivity. Official research has been conducted to compare Gludex’s measured outcomes with those of other standard diabetes medicines. These studies provide descriptive observations related to changes in blood sugar control and information about long-term considerations, such as the reported incidence of heart failure events.


Q: Is Gludex considered a long-term treatment?

A: Official prescribing information states that Gludex is intended for continuous, long-term use for managing Type 2 Diabetes. However, regulatory reviews have noted that while studies describe outcomes for a year, information on the sustained nature of measured blood sugar changes for periods much longer than one year may be limited.


Q: How quickly do people typically start to feel the effects of Gludex?

A: Regulatory documents describe the time to full clinical assessment of Gludex's effects on blood sugar levels. Official guidelines advise that a patient's blood sugar control be assessed after 8 to 12 weeks of treatment. This time frame is generally noted as the period needed to see the maximum therapeutic benefit of the medication.


Q: What is the expected duration of Gludex's effect after taking a dose?

A: The half-life of the active ingredient in Gludex (Rosiglitazone) is officially reported to be between 3 and 4 hours. The medication is typically taken once or twice daily, which allows it to maintain a continuous effect that supports the long-term management of blood sugar.


Q: What are the most commonly reported side effects of Gludex?

A: Official documents list the most commonly reported side effects—occurring in 1% to 10% of patients—as upper respiratory tract infection, headache, and edema (swelling caused by fluid retention). The complete list of reported effects is available in the official prescribing information.


Q: Does alcohol interact negatively with Gludex?

A: Official patient information notes that alcohol consumption may affect blood sugar levels, which can lead to complications like dangerously low blood sugar (hypoglycemia) or high blood sugar (hyperglycemia). Patients who consume alcohol can refer to the official patient information for guidance or consult a healthcare professional.


Q: What other medications are listed as potentially interacting with Gludex?

A: Gludex has documented interactions involving the CYP2C8 enzyme. This includes potent inhibitors like Gemfibrozil and potent inducers like Rifampin. Furthermore, using Gludex with Insulin has a pharmacodynamic interaction that increases the official risk of fluid retention.


Q: Is Gludex used for anything other than its main approved condition?

A: According to the official drug label, Gludex is only approved for use, along with diet and exercise, for the management of Type 2 Diabetes Mellitus.


Q: What class of drug does Gludex belong to?

A: Gludex is classified as an oral antidiabetic agent that belongs to the thiazolidinedione class of medications.


Q: Is it normal to feel a mild headache when starting Gludex?

A: Yes, headache is listed in official documents as one of the commonly reported side effects that occurred during clinical trials. Common effects are those reported in 1% to 10% of patients.


Q: What happens if a dose of Gludex is missed?

A: Official patient information advises that if a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular schedule should be continued. A double dose should not be taken to make up for a missed one, according to official patient information.


Q: Are there any specific foods or drinks to avoid while taking Gludex?

A: Official labels state that taking Gludex with or without food does not result in a clinically significant change in how the body uses the medicine. The medication is typically used in conjunction with a diet recommended for diabetes management.


Q: Can Gludex be taken with common pain relievers like ibuprofen?

A: Official warnings note that Gludex is associated with fluid retention. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen, are also linked to fluid retention. Taking both together may increase the risk of swelling (edema), and this potential for increased swelling is a point for review by a healthcare professional.


Q: Is Gludex safe for elderly patients?

A: Official regulatory information notes that elderly patients may be more sensitive to the effects of Gludex, particularly the potential for low blood sugar (hypoglycemia). Therefore, special caution is mentioned, especially for patients over 75 years of age, due to limited clinical experience in that age group.


Q: Is Gludex appropriate for use during pregnancy or while breastfeeding?

A: Official prescribing information states Gludex should generally not be used during pregnancy due to reported potential risks to the developing fetus. The manufacturer also advises against its use during breastfeeding, as it is unknown if the medicine passes into breast milk or if it affects the nursing infant.


Q: Where can I find the official prescribing information for Gludex?

A: Official prescribing and safety information is publicly available through various government health authorities in different countries. This includes the US Food and Drug Administration (FDA) Drug Labels, the European Medicines Agency (EMA) Summary of Product Characteristics, and official patient medication guides.


Q: Have there been any recent changes in the safety warnings for Gludex?

A: The FDA periodically reviews the safety data for Gludex. Following a review in recent years, the Risk Evaluation and Mitigation Strategy (REMS) was removed, as it was determined that the prescribing restrictions previously imposed were no longer needed to ensure the drug’s benefits outweigh its risks.


Q: Do studies suggest Gludex works better in certain patient groups?

A: Clinical trials describe the changes observed in blood sugar markers and safety outcomes across all studied patient populations. Findings from official studies help contextualize the observations made in these groups, but they do not predict individual responses.


Q: Does Gludex affect blood pressure?

A: Hypertension (high blood pressure) is listed in the official documents as one of the commonly reported side effects. This finding was observed in 1% to 10% of patients during clinical trials.


Q: Is Gludex associated with liver problems?

A: Official warnings note there have been rare reports of liver damage (hepatocellular injury). Increases in liver enzymes have been reported, sometimes leading to rare hepatic failure. Monitoring of liver function is recommended for patients taking Gludex.


Q: What official warnings are related to stopping Gludex suddenly?

A: Official guides state that discontinuation of Gludex should be done under the supervision of a doctor. Abruptly stopping any diabetes medicine may cause blood glucose levels to rise, which could lead to complications.


Q: Does Gludex require special monitoring or tests?

A: Yes, because of potential risks, Gludex requires special monitoring. Patients must be monitored for signs and symptoms of heart failure, and periodic liver enzyme tests are also recommended, particularly before starting the drug and throughout the course of therapy.


Q: What are 'Warnings and Precautions' as described in the Gludex label?

A: This is a standard section in the official drug label that describes important, clinically significant adverse reactions and potential risks. For Gludex, this includes statements about congestive heart failure, fluid retention, hepatic effects, and other serious considerations.


Q: How long has Gludex been approved for its current use?

A: Gludex (Rosiglitazone) has a long history of regulatory review. It was first approved for the management of Type 2 Diabetes in the late 1990s in countries like the US, where it was authorized in May 1999.


Q: Does taking Gludex affect driving ability or operating machinery?

A: Official labeling states that Gludex has a negligible influence on the ability to drive and use machines. However, if the medication is used in combination with other agents that can cause low blood sugar, patients are advised to exercise caution if they experience symptoms like dizziness or tiredness.


Q: What is the official information regarding overdose symptoms for Gludex?

A: Official documents state that limited data exists regarding human overdose. The expected primary consequence of taking too much of a drug that lowers blood sugar is hypoglycemia (low blood sugar). Symptoms may include confusion, agitation, or a rapid heart rate.


Q: Are there any known drug-disease interactions for Gludex?

A: Yes, official labeling notes that Gludex is contraindicated (should not be used) in patients with any stage of heart failure and serious hepatic impairment. It is also not indicated for patients with Type 1 Diabetes Mellitus or Diabetic Ketoacidosis.


Q: Is there a specific patient guide provided by the manufacturer of Gludex?

A: Yes, in the United States, the FDA requires that a specific Medication Guide be dispensed to all patients receiving Gludex. This guide contains important safety information to ensure patients are fully aware of the major risks and warnings associated with the medication.

How should Gludex be stored and disposed of?

How to Store and Dispose of Gludex (Rosiglitazone Tablets)

Official regulations require Gludex tablets to be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The medication must be protected from moisture to maintain its stability.

Storage Requirements

  • Store the tablets in the original container and ensure it is kept tightly closed.
  • Do not store the medication in the bathroom or any other high-humidity area.
  • It is mandatory to keep this medication out of the reach of children.

Disposal Instructions

Unused or expired Gludex should be discarded through an official medicine take-back program or pharmaceutical waste collection point. The medication must not be flushed down the toilet or poured into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Gludex found in:

A-Z Index: